Medscape publishes prescribing guidance for oral orforglipron in obesity
The clinician-facing piece addresses how the newly approved oral incretin fits into obesity prescribing practice.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 14 03:00 ETSource: Medscape
The wire
- 01Medscape has issued practice guidance on prescribing orforglipron, Eli Lilly's oral GLP-1 receptor agonist, for obesity.
- 02Prescribers weighing an oral option against injectable semaglutide and tirzepatide will want the dosing, titration and candidate-selection details.
- 03The item is educational commentary rather than new trial data; clinicians should work from the approved label.
From the source
Read at medscape.comPrescribing Orforglipron for Obesity